Terumo and Glooko announced a collaboration to integrate their technologies and create new diabetes data sharing solutions.

Glooko CEO Russ Johannesson discusses the company’s connected diabetes care strategy, including its recent agreement with Johns Hopkins HealthCare Solutions and acquisition of DIABNEXT.

L’équipe de la MedTech rejoint l’équipe de Glooko au sein du bureau parisien de la société et les deux plateformes sont désormais commercialisées sur le marché français. L’Américain ambitionne ainsi de développer sa communauté d’utilisateurs.

In its second acquisition of 2022 so far, Glooko is forging ahead in its mission not only to bulk up its digital diabetes management offerings but also to expand their reach around the world.

L’entreprise basée à Paris propose une plateforme de télésurveillance du diabète qui améliore la collaboration patient-praticien.

DIABNEXT s’est fait avaler par l’Américain Glooko, spécialisé lui aussi dans la télésurveillance des personnes atteintes de diabète. Il souhaite avec ce rachat conquérir de nouveaux patients en France.

Glooko is the latest newsmaker for diabetes tech – as the company is quickly hopping back on the M&A trail after the xBird deal in February. Glooko has acquired DIABNEXT, a company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers.

Digital diabetes management company Glooko has acquired Paris-based DIABNEXT, a fellow diabetes care platform.

Glooko announced that it acquired DIABNEXT, a developer of a digital health platform for managing diabetes and connecting to healthcare providers.

Das Berliner Digital-Health-Unternehmen xbird wird von der auf Diabetes-Telemonitoring spezialisierten Glooko aus den USA übernommen.